Dual Blockade of HER-2 Provides a Greater Magnitude of Benefit in Patients With Hormone-Negative Versus Hormone-Positive Breast Cancer.
作者： Mark Abramovitz , Casey Williams , Sibylle Loibl , Brian Leyland-Jones
DOI: 10.1016/J.CLBC.2016.06.004
关键词: Breast cancer 、 Tyrosine kinase 、 Capecitabine 、 Blockade 、 Trastuzumab 、 Lapatinib 、 Tyrosine-kinase inhibitor 、 Oncology 、 Internal medicine 、 Hormone receptor 、 Medicine
摘要: The dual small molecule tyrosine kinase inhibitor lapatinib blocks both human epidermal growth factor receptor (HER-1) and 2 (HER-2) activity by binding reversibly to the ATP-binding site of receptor's intracellular domain. Lapatinib, in combination with capecitabine, has been approved 2007 for treatment patients advanced HER-2+ breast cancer upon progressive disease following standard chemotherapy. Approval was also extended postmenopausal women hormone (HR)-positive HER-2-positive 2010. More recently, clinical trials that have investigated efficacy HER-2 blockade metastatic neoadjuvant settings. For example, 2013 European Medicines Agency trastuzumab HER-2+/HR- patients. We review results from studies present new post hoc analysis data according HR status. show appears provide a greater magnitude benefit HR- versus HR+ subgroup Finally, we examine potential molecularly subtyping tumors using PAM50 test as predictor response lapatinib.
sci-hub.se 参考文章(67)
Sara A Hurvitz, Fabrice Andre, Zefei Jiang, Zhimin Shao, Silvia P Neciosup, Max S Mano, Ling-Min Tseng, Qingyuan Zhang, Kunwei Shen, Donggeng Liu, Lydia M Dreosti, Jifeng Feng, Howard A Burris, Masakazu Toi, Marc E Buyse, David Cabaribere, Mary-Ann Lindsay, Tiffany Kunz, Shantha Rao, Lida B Pacaud, Tetiana Taran, Dennis Slamon, Abstract S6-01: Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1 Cancer Research. ,vol. 75, ,(2015) , 10.1158/1538-7445.SABCS14-S6-01
Steven Seelig, Carlos L. Arteaga, Walter King, F. Michael Yakes, Wichai Chinratanalab, Christoph A. Ritter, Herceptin-induced Inhibition of Phosphatidylinositol-3 Kinase and Akt Is Required for Antibody-mediated Effects on p27, Cyclin D1, and Antitumor Action Cancer Research. ,vol. 62, pp. 4132- 4141 ,(2002)
Mothaffar F Rimawi, Polly A Niravath, Tao Wang, Brent Rexer, Andres Forero, Antonio C Wolff, Rita Nanda, Anna M Storniolo, Ian Krop, Matthew P Goetz, Julie R Nangia, Sao Jiralerspong, Anne C Pavlick, Carolina Gutierrez, Rachel Schiff, Susan G Hilsenbeck, C Kent Osborne, Abstract S6-02: TBCRC023: A randomized multicenter phase II neoadjuvant trial of lapatinib plus trastuzumab, with endcorine therapy and without chemotherapy, for 12 vs. 24 weeks in patients with HER2 overexpressing breast cancer Cancer Research. ,vol. 75, ,(2015) , 10.1158/1538-7445.SABCS14-S6-02
Martine J Piccart-Gebhart, Andrew Peter Holmes, Jose Baselga, Evandro De Azambuja, Amylou C Dueck, Giuseppe Viale, Jo Anne Zujewski, Aron Goldhirsch, Sergio Santillana, Kathleen I Pritchard, Antonio C Wolff, Christian Jackisch, Istvan Lang, Michael Untch, Ian E Smith, Frances Boyle, Binghe Xu, Henry Leonidas Gomez, Richard D Gelber, Edith A Perez, None, First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). Journal of Clinical Oncology. ,vol. 32, pp. 502- 502 ,(2014) , 10.1200/JCO.2014.32.18_SUPPL.LBA4
Melissa A Troester, Jason I Herschkowitz, Daniel S Oh, Xiaping He, Katherine A Hoadley, Claire S Barbier, Charles M Perou, Gene expression patterns associated with p53 status in breast cancer BMC Cancer. ,vol. 6, pp. 276- 276 ,(2006) , 10.1186/1471-2407-6-276
Gabriela Alexe, Gul S. Dalgin, Daniel Scanfeld, Pablo Tamayo, Jill P. Mesirov, Charles DeLisi, Lyndsay Harris, Nicola Barnard, Maritza Martel, Arnold J. Levine, Shridar Ganesan, Gyan Bhanot, High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. Cancer Research. ,vol. 67, pp. 10669- 10676 ,(2007) , 10.1158/0008-5472.CAN-07-0539
Teemu T. Junttila, Robert W. Akita, Kathryn Parsons, Carter Fields, Gail D. Lewis Phillips, Lori S. Friedman, Deepak Sampath, Mark X. Sliwkowski, Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941 Cancer Cell. ,vol. 15, pp. 429- 440 ,(2009) , 10.1016/J.CCR.2009.03.020
G. Iyer, A. J. Hanrahan, M. I. Milowsky, H. Al-Ahmadie, S. N. Scott, M. Janakiraman, M. Pirun, C. Sander, N. D. Socci, I. Ostrovnaya, A. Viale, A. Heguy, L. Peng, T. A. Chan, B. Bochner, D. F. Bajorin, M. F. Berger, B. S. Taylor, D. B. Solit, Genome Sequencing Identifies a Basis for Everolimus Sensitivity Science. ,vol. 338, pp. 221- 221 ,(2012) , 10.1126/SCIENCE.1226344
Rohit Bhargava, David J Dabbs, Sushil Beriwal, Isil A Yildiz, Preeti Badve, Atilla Soran, Ronald R Johnson, Adam M Brufsky, Barry C Lembersky, Kandace P McGuire, Gretchen M Ahrendt, Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer Modern Pathology. ,vol. 24, pp. 367- 374 ,(2011) , 10.1038/MODPATHOL.2010.209
Katrien Berns, Hugo M. Horlings, Bryan T. Hennessy, Mandy Madiredjo, E. Marielle Hijmans, Karin Beelen, Sabine C. Linn, Ana Maria Gonzalez-Angulo, Katherine Stemke-Hale, Michael Hauptmann, Roderick L. Beijersbergen, Gordon B. Mills, Marc J. van de Vijver, René Bernards, A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. ,vol. 12, pp. 395- 402 ,(2007) , 10.1016/J.CCR.2007.08.030